Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma

Go back to Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma
(NYSE: COX) Delayed: 0.00 --0 (-0%)
Previous Close $0.00    52 Week High
Open $0.00    52 Week Low
Day High $0.00    P/E N/A 
Day Low $0.00    EPS
Volume